Methyl-aminolevulinic acid photodynamic therapy for actinic keratoses: A useful treatment or a risk factor? A retrospective study

Journal of Dermatological Treatment

Volumn 26, Issue 2, 2015, Pages 168-170

  Bardazzi, F ^a   Loi, C ^a   Magnano, M ^a   Burtica, E C ^a   Giordano, F ^b,c   Patrizi, A ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b INFN SEZIONE DI CATANIA   (Italy)

^c CERN   (Switzerland)

Author keywords

Carcinogenicity; Non melanoma skin cancer; Squamous cell carcinoma

Indexed keywords

AMINOLEVULINIC ACID METHYL ESTER; AMINOLEVULINIC ACID; METHYL 5-AMINOLEVULINATE; PHOTOSENSITIZING AGENT;

ACTINIC KERATOSIS; AGED; ARTICLE; BASAL CELL CARCINOMA; BOWEN DISEASE; CANCER RISK; CARCINOGENICITY; FACE; FEMALE; HAND; HUMAN; MAJOR CLINICAL STUDY; MALE; MALIGNANT TRANSFORMATION; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; RECURRENT DISEASE; RELAPSE; RETROSPECTIVE STUDY; RISK FACTOR; SCALP; SKIN CARCINOMA; THORAX; ADVERSE EFFECTS; ANALOGS AND DERIVATIVES; CARCINOMA, SQUAMOUS CELL; FOLLOW UP; KERATOSIS, ACTINIC; PHOTOCHEMOTHERAPY; PROCEDURES; SKIN NEOPLASMS; VERY ELDERLY;

AGED; AGED, 80 AND OVER; AMINOLEVULINIC ACID; CARCINOMA, SQUAMOUS CELL; FEMALE; FOLLOW-UP STUDIES; HUMANS; KERATOSIS, ACTINIC; MALE; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; RETROSPECTIVE STUDIES; RISK FACTORS; SKIN NEOPLASMS;

EID: 84930787266     PISSN: 09546634     EISSN: 14711753     Source Type: Journal    
DOI: 10.3109/09546634.2014.915004     Document Type: Article

References (12)

1. Lee Y, Baron ED. Photodynamic therapy: current evidence and applications in dermatology. Semin Cutan Med Surg. 2011;30: 199-209.
2. Ibbotson SH. Adverse effects of topical photodynamic therapy. Photodermatol Photoimmunol Photomed. 2011;27:116-30.
3. Morton CA, McKenna KE, Rhodes LE. Guidelines for topical photodynamic therapy: update. Br J Dermatol. 2009;159:1245-66.
4. Schreml S, Gantner S, Steinbaue J, et al. Melanoma promotion after photodynamic therapy of a suspected Bowen's disease lesion. Dermatology. 2009;219:279-81.
5. Maydan E, Nooothet PK, Goldman MP. Case reports: development of a keratoacanthoma after topical photodynamic therapy with 5-aminolevolunic acid. J Drugs Dermatol. 2006;5:804-6.
6. Yarma S, Holt PJA, Anstey AV. Erthroplasia of Queyrat treated by topical aminolaevulinic acid photodynamic therapy: a cautionary tale. Br J Dermatol. 2000;142:825-6.
7. Attili SK, Ibbotson SH, Fleming C. Role of a non-surgical therapies in the management of periocular basal cell carcinoma and squamous intra-epidermal carcinoma: a case series and review of the literature. Photoderm Photoimmun Photomed. 2012;28:68-79.
8. Kick G, Messer G, lewig G, et al. Strong and prolonged induction of c-jun and c-fos proto-oncogenes by photodynamic therapy. Br J Cancer. 1996;74:30-6.
9. Mroz P, Hamblin MR. The immunosuppressive side of PDT. Photochem Photobiol Sci. 2011;10:751-6.
10. Thanos SM, Halliday GM, Damian DL. Nicotinamide reduces photodynamic therapy-induced immunosuppression in humans. Br J Dermatol. 2012;167:631-6.
11. Traianou A, Ulrich M, Apalla Z, et al. Risk factors for actinic keratosis in eight European centres: a case-control study. Br J Dermatol. 2012;167:36-42.
12. Fuchs A, Marmur E. The kinetics of skin cancer: progressione of actinic keratosis to squamous cell carcinoma. Dermatol Surg. 2007; 33:1099-101.